Halozyme Therapeutics Inc. (0J2O)
LSE
Closed
Aug 25, 2026
Day's Range
107.2552 wk Range
59.85Overview - 0J2O - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
14.14B
P/E (Trailing)
‪0.35‬
Price / Book
‪85.53‬
EV / EBITDA
‪13.45‬
Profitability
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
143.94M
Float
112.16M
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.34%‬
Price stats
Beta
‪0.84‬
50-Day Avg
‪36.88‬
200-Day Avg
‪37.43‬
Market Cap - 0J2O - Halozyme Therapeutics Inc.
Peers - 0J2O - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0J2OLSEHalozyme Therapeutics Inc.15.60BMarket Cap+33.43%52-week change0.36P/E (Trailing)‪24.85%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0J2O - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
